Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS PEDIATRIC episodic migraine study of erenumab in children and adolescents
2023-504930-23-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in episodic migraine comparing Erenumab with Placebo (2 arms). Primary endpoint: Change from baseline in monthly migraine days to month 3. Planned start Jul 2019; status: authorised.
02
Drugs
erenumab
03
Conditions
episodic migraine
Beyond the preview
Go deeper on 2023-504930-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504930-23-00.